Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Vanderbilt University Medical Center

Sites in Nashville, TN

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1271
Shown on this page
12
Current sort
Recently updated
Campus scope
Vanderbilt University Medical Center, Nashville, TN
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Vanderbilt University Medical Center, Nashville, TN. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 889–900 of 1,271 matching trials with a site at Vanderbilt University Medical Center, Nashville, TN.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 4 Interventional

HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors

NCT02875314
Site status not listed — check the official record
View directory record Official record
Conditions
Medulloblastoma, Central Nervous System Embryonal Tumors
Interventions
Induction, Single Cycle Intensive Chemotherapy, Tandem 3 Cycle Intensive Chemotherapy
Drug
Lead sponsor
Parth Patel
Other
Eligibility
Up to 10 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
55
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Nov 5, 2026, 10:21 PM EST
Active, not recruiting Phase 2 Interventional Results available

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

NCT01415752
Site status not listed — check the official record
View directory record Official record
Conditions
Lymphoma, Mantle Cell Lymphoma
Interventions
rituximab, Bendamustine, bortezomib, lenalidomide
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2031
U.S. locations
416
States / cities
Anchorage, Alaska • Antioch, California • Fremont, California + 283 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Nov 5, 2026, 10:21 PM EST
Recruiting Not applicable Interventional

Suction vs Underwater Seal for HemoPneumoThoraX Trial

NCT07551791
Status at this site: Recruiting
View directory record Official record
Conditions
Hemothorax; Traumatic, Hemopneumothorax; Traumatic
Interventions
Suction, Water Seal
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Nov 5, 2026, 10:21 PM EST
Recruiting Phase 1 Interventional

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

NCT06917079
Status at this site: Recruiting
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer), Metastatic Non-Small Lung Cell Cancer, Metastatic Colorectal Cancer (CRC), KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12S, KRAS G12V, Metastatic Pancreatic Ductal Adenocarcinoma, Advanced Lung Carcinoma, Solid Tumor, Adult
Interventions
BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin), Pemetrexed, Cetuximab, mFOLFOX6, BBO-10203, mFOLFIRINOX, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Industry
Eligibility
18 Years and older
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
16
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Nov 5, 2026, 10:21 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Precision Brain Stimulation to Reduce Cannabis Craving in Schizophrenia

NCT07196462
Status at this site: Recruiting
View directory record Official record
Conditions
Cannabis Use, SCHIZOPHRENIA, Psychosis, rTMS
Interventions
3 Minute iTBS to the L DLPFC, One-Minute, Personalized, DMN Targeted CTBS
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Nov 5, 2026, 10:21 PM EST
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy

NCT05337553
Site status not listed — check the official record
View directory record Official record
Conditions
Spinal Muscular Atrophy, Neuromuscular Diseases, SMA
Interventions
taldefgrobep alfa, Placebo
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
4 Years to 21 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
30
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Nov 5, 2026, 10:21 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

NCT04956640
Site status not listed — check the official record
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Biliary Tract Neoplasms
Interventions
LY3537982, Pembrolizumab, Cetuximab, Pemetrexed, Cisplatin, Carboplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Nov 5, 2026, 10:21 PM EST
Recruiting Not applicable Interventional

Hemorrhage Elimination During Lumbar Puncture Using Ultrasound Measurements (HELPUS)

NCT07612644
Status at this site: Recruiting
View directory record Official record
Conditions
Lumbar Puncture
Interventions
ultrasound contrast
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
1 Day to 12 Months
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Nov 5, 2026, 10:21 PM EST
Recruiting No phase listed Observational

Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)

NCT05462574
Status at this site: Recruiting
View directory record Official record
Conditions
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
Interventions
No Intervention
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Nov 5, 2026, 10:21 PM EST
Recruiting Not applicable Interventional

Use of CereGate Therapy for Freezing of Gait in PD

NCT05292794
Status at this site: Recruiting
View directory record Official record
Conditions
Parkinson Disease, Freezing of Gait, Deep Brain Stimulation
Interventions
CereGate Software; BSN cDBS Programmer; BSN Burst Programmer
Device
Lead sponsor
CereGate Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Redwood City, California • Aurora, Colorado • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Nov 5, 2026, 10:21 PM EST
Recruiting Not applicable Interventional

REmotely Monitored, Mobile Health Supported Multidomain Rehabilitation Program With High Intensity Interval Training for COVID-19

NCT05218083
Status at this site: Recruiting
View directory record Official record
Conditions
COVID-19, Critical Illness, ICU Acquired Weakness, PICS, Cardiorespiratory Fitness
Interventions
REmotely monitored, Mobile health supported Multidomain Rehabilitation Program with High Intensity Interval Training (REMM-HIIT)
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Birmingham, Alabama • Lexington, Kentucky • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Nov 5, 2026, 10:21 PM EST
Active, not recruiting Phase 3 Interventional

Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta

NCT05972551
Site status not listed — check the official record
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Romosozumab, Bisphosphonate
Drug
Lead sponsor
Amgen
Industry
Eligibility
5 Years to 17 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Nov 5, 2026, 10:21 PM EST

About this Vanderbilt University Medical Center institution page

What this page lists
ClinicalTrials.gov records that list Vanderbilt University Medical Center in Nashville, TN as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.